Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
30 employees
Bedrock Therapeutics: Pioneering AAV gene therapy for ocular, hematologic, and other diseases.
HQ
Founded
2019
Bedrock Therapeutics is an AAV gene therapy research and development company focused on creating platform and disease-specific technologies for treating ocular, hematologic, and other diseases. Their innovative technologies include human-tropic and antibody-evading AAV capsids and single-chain immune modulators (scIMs).
Key achievements include advancements in gene therapy platforms that address critical medical needs. The team comprises experts like Brian Gilger, Matthew Hirsch, Chengwen Li, and Roger “Bryan” Sutton, contributing to the company's impact in the biotech industry.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Gene Therapy
Technology
Biotech
Tags
Therapeutics
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Bedrock Therapeutics founded?
Bedrock Therapeutics was founded in 2019.
Where is Bedrock Therapeutics's headquarters located?
Bedrock Therapeutics's headquarters is located in Raleigh, NC, US.
When was Bedrock Therapeutics's last funding round?
Bedrock Therapeutics's most recent funding round was for $75k (USD) in September 2022.
How many employees does Bedrock Therapeutics have?
Bedrock Therapeutics has 30 employees as of Feb 4, 2024.
How much has Bedrock Therapeutics raised to-date?
As of July 05, 2023, Bedrock Therapeutics has raised a total of $84.6k (USD) since Sep 22, 2022.
Add Comparison
Total Raised to Date
$84.6k
USD
Last Update Sep 22, 2022
Last Deal Details
$75k
USD
Sep 22, 2022
Grant
Current Employees
30
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts